• Investing
  • Stock
  • Economy
  • Editor’s Pick
Portfolio Performance Today
Stock

GSK names Luke Miels as next CEO after Emma Walmsley steps down; shares jump

by September 29, 2025
by September 29, 2025

GSK announced on Monday that Chief Executive Emma Walmsley will step down after nine years in the role, with current Chief Commercial Officer Luke Miels set to take over on January 1.

The transition marks a major shift for the UK-based drugmaker as it seeks to define its long-term growth strategy.

Walmsley, who took the top job in 2017, guided GSK through a period of reinvention, focusing on cancer and infectious diseases while restructuring the business following the 2022 demerger of its consumer healthcare arm Haleon.

Despite challenges, including declining revenue from key medicines and shareholder pressure, she was credited with revitalising the company’s research pipeline and stabilising its balance sheet.

“2026 is a pivotal year for GSK to define its path for the decade ahead, and I believe the right moment for new leadership,” Walmsley said in a statement.

She will step down from the board on December 31 but remain with the company until September 2026 to ensure a smooth handover.

Market welcomes leadership change: who is Luke Miels?

Shares of GSK rose 3.6% on Monday, making it one of the strongest performers on the FTSE 100 index.

Investors appeared to welcome the appointment of Miels, who has been with the company since 2017 and played a key role in building its oncology and respiratory portfolio.

Chairman Jonathan Symonds praised Miels, 50, for his extensive experience in biopharma development and commercialization.

“He has outstanding global expertise and a deep understanding of GSK,” Symonds said.

Miels previously held senior roles at AstraZeneca, Roche, and Sanofi before joining GSK.

He is expected to steer the company toward its goal of achieving more than £40 billion ($53.7 billion) in annual sales by 2031, with multiple new drug launches anticipated by 2027.

US expansion amid political pressures

The leadership announcement comes shortly after GSK unveiled plans to invest $30 billion in the United States over the next five years.

The commitment includes a $1.2 billion outlay for advanced manufacturing facilities and the use of artificial intelligence in next-generation laboratories.

The move reflects increasing pressure from the Trump administration for pharmaceutical companies to shift production to the US, where the government has threatened tariffs of up to 250% on imported medicines.

Several drugmakers have already scaled back or redirected spending away from the UK in response, with nearly £2 billion in planned investments cancelled this year.

Outlook under Miels

Walmsley’s tenure saw GSK shares fall nearly 6% overall, even as she repositioned the company for long-term growth.

With Miels at the helm, the focus will be on accelerating commercial execution, expanding the specialty medicines portfolio, and navigating regulatory and political challenges in key markets.

Analysts say the leadership change could mark a new era for GSK, as it seeks to balance scientific innovation with geopolitical and economic pressures that are reshaping the global pharmaceuticals landscape.

The post GSK names Luke Miels as next CEO after Emma Walmsley steps down; shares jump appeared first on Invezz

0 comment
0
FacebookTwitterPinterestEmail

previous post
Tata Capital IPO aims to raise $1.7B in India’s largest 2025 listing
next post
European stocks open higher: DAX up 0.47%, FTSE climbs 0.34%

Related Posts

Cyberattack halts Asahi production, disrupts Japan’s beer supply

October 3, 2025

Europe markets open: Stoxx 600 rises 0.4%, extending...

October 3, 2025

Bitcoin ETFs see over $600M in inflows as...

October 3, 2025

Stockholm leads Europe in IPO activity with $6.8...

October 3, 2025

Indonesia suspends TikTok licence after data refusal during...

October 3, 2025

Why the Thai baht’s climb against US dollar...

October 3, 2025

OpenAI valuation hits $500 billion as employees sell...

October 2, 2025

Here’s why JPMorgan, Morningstar are bullish on Alibaba...

October 2, 2025

Europe markets open: Stoxx 600 jumps 0.6%, led...

October 2, 2025

Will the Tesco share price hit 500p as...

October 2, 2025

Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.

By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

Recent Posts

  • What I Saw in Milei’s Argentina

    October 3, 2025
  • Tariffs Rest on Distrust of Citizens

    October 3, 2025
  • Cyberattack halts Asahi production, disrupts Japan’s beer supply

    October 3, 2025
  • Europe markets open: Stoxx 600 rises 0.4%, extending its record-setting rally

    October 3, 2025
  • Bitcoin ETFs see over $600M in inflows as BTC price nears $120K

    October 3, 2025
  • Stockholm leads Europe in IPO activity with $6.8 billion raised

    October 3, 2025

Editors’ Picks

  • 1

    Meta executives eligible for 200% salary bonus under new pay structure

    February 21, 2025
  • 2

    Walmart earnings preview: What to expect before Thursday’s opening bell

    February 20, 2025
  • 3

    New FBI leader Kash Patel tapped to run ATF as acting director

    February 23, 2025
  • 4

    Cramer reveals a sub-sector of technology that can withstand Trump tariffs

    March 1, 2025
  • 5

    Anthropic’s newly released Claude 3.7 Sonnet can ‘think’ as long as the user wants before giving an answer

    February 25, 2025
  • 6

    Nvidia’s investment in SoundHound wasn’t all that significant after all

    March 1, 2025
  • 7

    Pop Mart reports 188% profit surge, plans aggressive global expansion

    March 26, 2025

Categories

  • Economy (2,770)
  • Editor's Pick (279)
  • Investing (185)
  • Stock (1,885)
  • About us
  • Contact us
  • Privacy Policy
  • Terms & Conditions

Copyright © 2025 Portfolioperformancetoday.com All Rights Reserved.

Portfolio Performance Today
  • Investing
  • Stock
  • Economy
  • Editor’s Pick
Portfolio Performance Today
  • Investing
  • Stock
  • Economy
  • Editor’s Pick
Copyright © 2025 Portfolioperformancetoday.com All Rights Reserved.

Read alsox

Palantir co-founder: US must prevent Iranian nukes

June 21, 2025

Asia markets on Friday: Hang Seng, Nifty...

April 12, 2025

Thames Water hit with record £123m fine...

May 28, 2025